Research graph
References from Systematic Review: Inclusion of Patients With Difficult‐to‐Treat Inflammatory Bowel Disease in Randomized Controlled Trials of Advanced Therapies. Local targets link to admitted publications; unresolved targets remain external evidence.
ACG Clinical Guideline Update: Ulcerative Colitis in Adults
10.14309/ajg.0000000000003463 · 2025 · External reference
ACG Clinical Guideline: Management of Crohn's Disease in Adults
10.14309/ajg.0000000000003465 · 2025 · External reference
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
2021 · External reference
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
10.1093/ecco-jcc/jjae091 · 2024 · External reference
Difficult‐To‐Treat Inflammatory Bowel Disease: Results From an International Consensus Meeting
10.1016/s2468-1253(23)00154-1 · 2023 · External reference
Patients Included in Clinical Trials of Biological Drugs for Inflammatory Bowel Disease Do Not Represent the Real‐World Population
10.14309/ajg.0000000000003670 · 2026 · External reference
Recommendations for the Extraction, Analysis, and Presentation of Results in Scoping Reviews
10.11124/jbies-22-00123 · 2023 · External reference
Best Practice Guidance and Reporting Items for the Development of Scoping Review Protocols
10.11124/jbies-21-00242 · 2022 · External reference
PRISMA Extension for Scoping Reviews (PRISMA‐ScR): Checklist and Explanation
10.7326/m18-0850 · 2018 · External reference
Systematic Review and Meta‐Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis
10.1093/ecco-jcc/jjab135 · 2022 · External reference
Clinical, Endoscopic, and Safety Placebo Rates in Induction and Maintenance Trials of Crohn's Disease: Meta‐Analysis of Randomised Controlled Trials
10.1093/ecco-jcc/jjab194 · 2022 · External reference
Vedolizumab for the Treatment of Chronic Pouchitis
10.1056/nejmoa2208450 · 2023 · External reference
Abatacept for Crohn's Disease and Ulcerative Colitis
10.1053/j.gastro.2012.04.010 · 2012 · External reference
Efficacy and Safety of the Anti‐Mucosal Addressin Cell Adhesion Molecule‐1 Antibody Ontamalimab in Patients With Moderate‐to‐Severe Ulcerative Colitis or Crohn's Disease
2023 · External reference
Subcutaneous Infliximab (CT‐P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)
10.1053/j.gastro.2024.05.006 · 2024 · External reference
Efficacy and Safety of Vedolizumab and Tofacitinib (VETO) Combination Therapy in Refractory Ulcerative Colitis Unresponsive to Anti‐TNF and a Second‐Line Advanced Therapy: A Prospective Cohort Nested Within a Randomised Trial
10.1111/apt.70309 · 2026 · External reference
Efficacy and Safety of the Interleukin‐10–Fragment F8 Fusion Protein PF‐06687234 as Add‐On Therapy to Infliximab in Patients With Active Ulcerative Colitis: A Randomized, Phase IIa Clinical Trial
10.1177/17562848251410784 · 2026 · External reference
Efficacy and Safety of Duvakitug in Patients With Ulcerative Colitis (RELIEVE UCCD): A Phase 2b, Randomised, Placebo‐Controlled Trial
10.1016/s2468-1253(26)00120-2 · 2026 · External reference
Efficacy and Safety of Subcutaneous Guselkumab Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (ASTRO): A Double‐Blind, Treat‐Through, Randomised, Placebo‐Controlled, Phase 3 Trial
10.1016/s2468-1253(25)00322-x · 2026 · External reference
Anti‐TL1A Antibody, Afimkibart, in Moderately‐To‐Severely Active Ulcerative Colitis (TUSCANY‐2): A Multicentre, Double‐Blind, Treat‐Through, Multi‐Dose, Randomised, Placebo‐Controlled, Phase 2b Trial
10.1016/s2468-1253(25)00129-3 · 2025 · External reference
Tamuzimod in Patients With Moderately‐To‐Severely Active Ulcerative Colitis: A Multicentre, Double‐Blind, Randomised, Placebo‐Controlled, Phase 2 Induction Trial
10.1016/s2468-1253(24)00386-8 · 2025 · External reference
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis (QUASAR): Phase 3 Double‐Blind, Randomised, Placebo‐Controlled Induction and Maintenance Studies
10.1016/s0140-6736(24)01927-5 · 2025 · External reference
Phase 2 Trial of Anti‐TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis
10.1056/nejmoa2314076 · 2024 · External reference
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials
10.1001/jama.2024.12414 · 2024 · External reference
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
10.1053/j.gastro.2023.08.038 · 2023 · External reference
Filgotinib as Induction and Maintenance Therapy for Ulcerative Colitis (SELECTION): A Phase 2b/3 Double‐Blind, Randomised, Placebo‐Controlled Trial
10.1016/s0140-6736(21)00666-8 · 2021 · External reference
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis
10.1056/nejmoa2033617 · 2021 · External reference
Cobitolimod for Moderate‐To‐Severe, Left‐Sided Ulcerative Colitis (CONDUCT): A Phase 2b Randomised, Double‐Blind, Placebo‐Controlled, Dose‐Ranging Induction Trial
10.1016/s2468-1253(20)30301-0 · 2020 · External reference
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis
10.1053/j.gastro.2020.02.030 · 2020 · External reference
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
10.1056/nejmoa1900750 · 2019 · External reference
Efficacy and Safety of Duvakitug in Patients With Crohn's Disease (RELIEVE UCCD): A Phase 2b, Randomised, Placebo‐Controlled Trial
10.1016/s2468-1253(26)00119-6 · 2026 · External reference
Efficacy and Safety of Intravenous Induction and Subcutaneous Maintenance Therapy With Guselkumab for Patients With Crohn's Disease (GALAXI‐2 and GALAXI‐3): 48‐Week Results From Two Phase 3, Randomised, Placebo and Active Comparator‐Controlled, Double‐Blind, Triple‐Dummy Trials
10.1016/s0140-6736(25)00681-6 · 2025 · External reference
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study
10.1053/j.gastro.2025.02.033 · 2025 · External reference
Efficacy and Safety of Filgotinib as Induction and Maintenance Therapy for Crohn's Disease (DIVERSITY): A Phase 3, Double‐Blind, Randomised, Placebo‐Controlled Trial
10.1016/s2468-1253(24)00272-3 · 2025 · External reference
Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulising Crohn's Disease [DIVERGENCE 2]: A Phase 2, Randomised, Placebo‐Controlled Trial
10.1093/ecco-jcc/jjae003 · 2024 · External reference
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI‐1 Study
10.1053/j.gastro.2022.01.047 · 2022 · External reference
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease
10.1053/j.gastro.2020.01.047 · 2020 · External reference
A Phase 2, Randomized, Placebo‐Controlled Study Evaluating Matrix Metalloproteinase‐9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease
2018 · External reference
Certolizumab Pegol for Active Crohn's Disease: A Placebo‐Controlled, Randomized Trial
10.1016/j.cgh.2011.04.031 · 2011 · External reference
AST‐120 (Spherical Carbon Adsorbent) in the Treatment of Perianal Fistulae in Mild‐To‐Moderate Crohn's Disease: FHAST‐1, a Phase 3, Multicenter, Placebo‐Controlled Study
10.1097/mib.0000000000000031 · 2014 · External reference
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM Trial
10.1053/j.gastro.2006.11.041 · 2007 · External reference
Adalimumab for Maintenance Treatment of Crohn's Disease: Results of the CLASSIC II Trial
10.1136/gut.2006.106781 · 2007 · External reference
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
10.1056/nejmoa030815 · 2004 · External reference
Tacrolimus for the Treatment of Fistulas in Patients With Crohn's Disease: A Randomized, Placebo‐Controlled Trial
10.1016/s0016-5085(03)00877-1 · 2003 · External reference
Infliximab for the Treatment of Fistulas in Patients With Crohn's Disease
10.1056/nejm199905063401804 · 1999 · External reference
The Four Epidemiological Stages in the Global Evolution of Inflammatory Bowel Disease
10.1038/s41575-020-00360-x · 2021 · External reference
Primary Non‐Response to Tumor Necrosis Factor Antagonists Is Associated With Inferior Response to Second‐Line Biologics in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta‐Analysis
10.1093/ecco-jcc/jjy004 · 2018 · External reference
Prevalence, Characteristics, Management, and Outcomes of Difficult‐To‐Treat Inflammatory Bowel Disease
10.1093/ecco-jcc/jjae145 · 2025 · External reference
Difficult‐To‐Treat Inflammatory Bowel Disease: Results From a Global IOIBD Survey
10.1016/s2468-1253(22)00085-1 · 2022 · External reference
P1164 Prevalence and Risk Factors of Difficult‐To‐Treat Inflammatory Bowel Disease in Crete
10.1093/ecco-jcc/jjaf231.1345 · 2026 · External reference
P0972 Prevalence of and Risk Factors for Difficult‐To‐Treat Inflammatory Bowel Disease in Korean
10.1093/ecco-jcc/jjaf231.1153 · 2026 · External reference
Clinical Characterization and Healthcare Burden of Difficult‐To‐Treat Inflammatory Bowel Disease in Latin America: A Real‐World Registry‐Based Study
10.1093/crocol/otag058 · 2026 · External reference
Differential Efficacy of Advanced Therapies in Inducing Remission in Ulcerative Colitis Based on Prior Exposure to TNF Antagonists
2024 · External reference
Real‐World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry
10.1111/apt.70783 · 2026 · External reference
Real‐World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry
10.1002/ueg2.70223 · 2026 · External reference
Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients With Crohn's Disease: A GETAID Multicentre Cohort Study
10.1111/apt.70073 · 2025 · External reference
Competition for Clinical Trials in Inflammatory Bowel Diseases
10.1053/j.gastro.2019.08.020 · 2019 · External reference
